Arovella Therapeutics (ASX:ALA) ROCE % : -133.44% (As of Jun. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Arovella Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Arovella Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2024 was -133.44%.

Arovella Therapeutics ROCE % Historical Data

The historical data trend for Arovella Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics ROCE % Chart

Arovella Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROCE %

Get a 7-Day Free Trial

-108.07

-73.32

-100.94

-176.84

-116.24

Arovella Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-141.80	-129.17	-312.65	-227.15	-133.44

Arovella Therapeutics ROCE % Calculation

Arovella Therapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	-8.737	/	( ( (5.471 - 1.682)	+	(13.285 - 2.041) )	/ 2 )
	=	-8.737	/	( (3.789	+	11.244)	/ 2 )
	=	-8.737	/	7.5165
	=	-116.24 %

Arovella Therapeutics's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-9.6	/	( ( (5.328 - 2.184)	+	(13.285 - 2.041) )	/ 2 )
	=	-9.6	/	( ( 3.144	+	11.244 )	/ 2 )
	=	-9.6	/	7.194
	=	-133.44 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Arovella Therapeutics (ASX:ALA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Arovella Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arovella Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

E4NA:Germany

Address

84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072

Website

https://www.arovella.com

Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

Arovella Therapeutics Headlines

No Headlines